Russian drugmakers strengthen positions in insulin-containing drugs market

Russian drug manufacturers are eliminating global players from the domestic insulin market, as their sales are steadily growing, The Pharma Letter’s local correspondent reports.

According to analysts’ predictions, in the segment of public procurements of insulin-containing drugs, local producers will account for almost 44% of contracts by the end of the current year.

This will be also due to those preferences that will be provided by the government for such companies at state auctions. According to data of the Russian research agency in the field of pharmaceutics DSM Group, in 2024 the share of Russian companies in the overall structure of insulin-containing drugs in Russia value terms accounted for 27.2%, or 7.4 billion roubles ($87.6 million) and 41.7% in terms of volume up to 5.6 million units.